These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 1581831)

  • 1. Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines.
    Slavin S; Ackerstein A; Weiss L; Nagler A; Or R; Naparstek E
    Cancer Invest; 1992; 10(3):221-7. PubMed ID: 1581831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders: I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL-2-activated cell-mediated immunotherapy.
    Weiss L; Reich S; Slavin S
    Cancer Invest; 1992; 10(1):19-26. PubMed ID: 1735011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-2 activated cell-mediated immunotherapy: control of minimal residual disease in malignant disorders by allogeneic lymphocytes and IL-2.
    Slavin S; Ackerstein A; Kedar E; Weiss L
    Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():86-90. PubMed ID: 2390644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
    Weiss L; Reich S; Slavin S
    Cytokines Cell Mol Ther; 1999 Sep; 5(3):145-52. PubMed ID: 10641572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of recombinant human interleukin-2 in conjunction with syngeneic bone marrow transplantation in mice as a model for control of minimal residual disease in malignant hematologic disorders.
    Ackerstein A; Kedar E; Slavin S
    Blood; 1991 Sep; 78(5):1212-5. PubMed ID: 1878588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic cell-mediated immunotherapy for eradication of minimal residual disease: comparison of T-cell and IL-2 activated killer (LAK) cell-mediated adoptive immunotherapy in murine models.
    Vourka-Karussis U; Ackerstein A; Pugatsch T; Slavin S
    Exp Hematol; 1999 Mar; 27(3):461-9. PubMed ID: 10089908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
    J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 2. The role of non-activated and rIL-2-activated CD4+ and CD8+ T cells in immunotherapy for leukemia.
    Weiss L; Reich S; Slavin S
    Cytokines Cell Mol Ther; 1999 Sep; 5(3):153-8. PubMed ID: 10641573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of graft versus leukemia effects by cell-mediated lymphokine-activated immunotherapy after syngeneic bone marrow transplantation in murine B cell leukemia.
    Weiss L; Nusair S; Reich S; Sidi H; Slavin S
    Cancer Immunol Immunother; 1996 Oct; 43(2):103-8. PubMed ID: 8954144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens.
    Cohen P; Vourka-Karussis U; Weiss L; Slavin S
    J Immunol; 1993 Nov; 151(9):4803-10. PubMed ID: 8409438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of purified CD8+ T cells in graft-versus-leukemia activity and engraftment after allogeneic bone marrow transplantation.
    Palathumpat V; Dejbakhsh-Jones S; Strober S
    Transplantation; 1995 Aug; 60(4):355-61. PubMed ID: 7652765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokine-mediated immunotherapy following autologous bone marrow transplantation in lymphoma and evidence of interleukin-2-induced immunomodulation in allogeneic transplants.
    Slavin S; Nagler A
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S59-67. PubMed ID: 9457396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy of minimal residual disease in conjunction with autologous and allogeneic bone marrow transplantation (BMT).
    Slavin S; Or R; Kapelushnik Y; Drakos P; Ackerstein A; Vourka-Karussis U; Weiss L; Nagler A
    Leukemia; 1992 Nov; 6 Suppl 4():164-6. PubMed ID: 1434823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of BCL1 leukemia by transplantation of low density fractions of allogeneic bone marrow and spleen cells.
    Palathumpat V; Holm B; Dejbakhsh-Jones S; Strober S
    J Immunol; 1992 May; 148(10):3319-26. PubMed ID: 1578152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonmyeloablative allogeneic bone marrow transplantation as immunotherapy for hematologic malignancies and metastatic solid tumors in preclinical models.
    Prigozhina TB; Gurevitch O; Morecki S; Yakovlev E; Elkin G; Slavin S
    Exp Hematol; 2002 Jan; 30(1):89-96. PubMed ID: 11823042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.
    Pavletic Z; Benyunes MC; Thompson JA; Lindgren CG; Massumoto C; Alderson MR; Buckner CD; Fefer A
    Exp Hematol; 1993 Sep; 21(10):1371-8. PubMed ID: 8359237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of graft-versus-leukemia (GVL) activity in murine leukemia models after IL-2 pretreatment of syngeneic and allogeneic bone marrow grafts.
    Zeis M; Uharek L; Glass B; Gaska T; Gassmann W; Mueller-Ruchholtz W
    Bone Marrow Transplant; 1994 Nov; 14(5):711-5. PubMed ID: 7889004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between enhancement of graft-versus-leukemia effects following allogeneic bone marrow transplantation by rIL-2 and increased frequency of cytotoxic T-lymphocyte precursors in murine myeloid leukemia.
    Leshem B; Vourka-Karussis U; Slavin S
    Cytokines Cell Mol Ther; 2000 Sep; 6(3):141-7. PubMed ID: 11140883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression and elimination of BCL1 leukemia by allogeneic bone marrow transplantation.
    Weiss L; Morecki S; Vitetta ES; Slavin S
    J Immunol; 1983 May; 130(5):2452-5. PubMed ID: 6339628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention and treatment of relapse by bone marrow transplantation.
    Slavin S; Weiss L; Ackerstein A; Vourka-Karussis U; Morecki S; Or R; Nagler A; Kapelushnik J; Delukina M; Drakos P
    Bone Marrow Transplant; 1993; 12 Suppl 3():S54-6. PubMed ID: 8124259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.